BR112017001474A2 - mutations in the extracellular domain iii of the epidermal growth factor receptor gene - Google Patents

mutations in the extracellular domain iii of the epidermal growth factor receptor gene

Info

Publication number
BR112017001474A2
BR112017001474A2 BR112017001474-2A BR112017001474A BR112017001474A2 BR 112017001474 A2 BR112017001474 A2 BR 112017001474A2 BR 112017001474 A BR112017001474 A BR 112017001474A BR 112017001474 A2 BR112017001474 A2 BR 112017001474A2
Authority
BR
Brazil
Prior art keywords
seq
egfr
mutations
amino acid
cetuximab
Prior art date
Application number
BR112017001474-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Bardelli Alberto
Arena Sabrina
Montagut Viladot Clara
Albanell Mestres Joan
Rovira Guerin Ana
Bellosillo Paricio Beatriz
Dalmases Massegú Alba
Original Assignee
Fundació Institut Mar D´Investigacions Mèdiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut Mar D´Investigacions Mèdiques filed Critical Fundació Institut Mar D´Investigacions Mèdiques
Publication of BR112017001474A2 publication Critical patent/BR112017001474A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/485Epidermal growth factor [EGF] (urogastrone)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017001474-2A 2014-07-28 2014-12-30 mutations in the extracellular domain iii of the epidermal growth factor receptor gene BR112017001474A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382288.0 2014-07-28
EP14382288 2014-07-28
PCT/EP2014/079477 WO2016015788A1 (en) 2014-07-28 2014-12-30 Mutations in the extracellular domain iii of epidermal growth factor receptor gene

Publications (1)

Publication Number Publication Date
BR112017001474A2 true BR112017001474A2 (en) 2018-02-20

Family

ID=51225482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001474-2A BR112017001474A2 (en) 2014-07-28 2014-12-30 mutations in the extracellular domain iii of the epidermal growth factor receptor gene

Country Status (8)

Country Link
US (2) US11015225B2 (https=)
EP (2) EP3428185A1 (https=)
JP (1) JP6905464B2 (https=)
CN (1) CN106573967B (https=)
BR (1) BR112017001474A2 (https=)
CA (1) CA2954952C (https=)
ES (1) ES2693080T3 (https=)
WO (1) WO2016015788A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112064A2 (en) 2015-01-06 2016-07-14 The Johns Hopkins University Response to egfr blockade
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用
CN115947823B (zh) * 2022-09-29 2024-05-03 江汉大学 一种用于筛选结合和/或激活egfr的有毒金属的表达蛋白及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
CN101501211A (zh) * 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
SG10201605049QA (en) * 2011-05-20 2016-07-28 Fluidigm Corp Nucleic acid encoding reactions
EP2554551A1 (en) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene

Also Published As

Publication number Publication date
US20170260250A1 (en) 2017-09-14
CN106573967B (zh) 2022-02-18
CA2954952C (en) 2023-05-23
EP3174896A1 (en) 2017-06-07
ES2693080T3 (es) 2018-12-07
EP3174896B1 (en) 2018-08-22
CN106573967A (zh) 2017-04-19
US11015225B2 (en) 2021-05-25
JP6905464B2 (ja) 2021-07-21
CA2954952A1 (en) 2016-02-04
EP3428185A1 (en) 2019-01-16
WO2016015788A1 (en) 2016-02-04
JP2017522890A (ja) 2017-08-17
US20210262037A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
ES2426814T3 (es) Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr
ES2458626T5 (es) Mutaciones en K-ras y terapia con anticuerpos anti-EGFr
ES2995194T3 (en) Method for the prognosis and treatment of cancer metastasis
CA2842270C (en) Mutations in the epidermal growth factor receptor gene
KR20160061424A (ko) 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법
US20210262037A1 (en) Methods of treating cancer based on identifying mutations in the extracellular domain iii of epidermal growth factor receptor gene
CA2819080A1 (en) Agtr1 as a marker for bevacizumab combination therapies
CA2683815A1 (en) Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to her2-targeting therapy
US20180147231A1 (en) Method for treatment and prognosis of colorectal cancer
US7985559B2 (en) Methods of selecting epidermal growth factor receptor (EGFR) binding agents
CA2870015A1 (en) Autoimmune antibodies
AU2016250348A1 (en) K-ras mutations and anti-EGFr antibody therapy field

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]